Selank — reference
A synthetic analogue of tuftsin, used in Russia as an anxiolytic without the sedation or dependence of benzodiazepines.
Regulatory status
Not FDA-Approved. Approved in Russia; not FDA-approved in the US.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~20 minutes. Similar evidence base/limitations as Semax.
This figure is tagged Limited data in our evidence system. The available data does not support a confident single figure, so this entry is flagged accordingly. Read any curve built from it as illustrative only. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Selank FDA-approved?
What is the half-life of Selank?
How reliable is that half-life figure?
What cautions are associated with Selank?
Does Peptide Plug publish dosing for Selank?
Does Peptide Plug sell Selank?
Related tools
Free, no account required.
The public research page intentionally does not publish dosing. Pro subscribers can open the separate Protocol Library for structured indication, frequency, duration, notes, and review-first Cycle Builder import when a matching reference is available.
View Protocol Reference